Skip to content Skip to navigation

Can ‘Big Data’ Help Increase Drug Safety?

October 9, 2013
by John DeGaspari
| Reprints
Researchers use an EHR database to reduce adverse effects

Using the Food and Drug Administration's Adverse Event Reporting System (FAERS), a hospital electronic health records database, and an animal model, a team of researchers at the Icahn School of Medicine at Mount Sinai report that by adding a second drug to the diabetes drug rosiglitazone, adverse events dropped enormously. That suggests that drugs could be repurposed to improve drug safety, including lowering the risk of heart attacks. The research is published online Oct. 9 in the journal Science Translational Medicine.

 “Big data systems have a wealth of data, and when studied appropriately, can point to potentially safer combinations,” said Ravi Iyengar Ph.D., professor of pharmacology and director of the Systems Biology Center at the Icahn School of Medicine at Mount Sinai. He said that findings from big data analyses, although preliminary, can point to potentially safer combinations that can subsequently be tested in clinical trial. “We may be able to use FDA-approved drugs to prevent adverse events,” he said

In this study, investigators studied how drug combinations act through networks within cells, focusing on the diabetes drug rosiglitazone, an effective drug in controlling blood glucose. However, rosiglitazone has a serious side effect, increased heart attacks, which have restricted its use markedly. Investigators analyzed data from the FDAERS to see if second drugs could lower the rate heart attacks, and compared their results with Mount Sinai's electronic health records system. They found that the drug exanatide, often given along with rosiglitazone to get better control of blood glucose, also very substantially reduced the heart attack rate in rosiglitazone users. Iyengar’s team also found nearly 19,000 other drug combinations in the FDA database, where the second drug appears to reduce a wide range of side effects of the first drug.

The research team said that that the results are a valid starting point for developing clinical trials of safer drug combinations, and urged researchers and clinicians to contribute to big databases, such as the FDA’s Adverse Event Reporting System.

 

Topics

News

CMS Extends Deadline for eCQM Data Submission

CMS is extending the deadline for eligible hospitals in the Hospital Inpatient Quality Reporting (IQR) and Meaningful Use programs to submit their electronic clinical quality measure (eCQM) data from 2016.

NorthShore Revalidated by HIMSS Analytics as Stage 7 Worthy

Due to its continued use of IT to improve patient care and reduce costs, Chicago-based NorthShore University HealthSystem has received Stage 7 revalidation on HIMSS’ acute care EMRAM and outpatient EMRAM for its hospitals and associated clinics.

Cybersecurity Consulting Firm CynergisTek Acquired by Auxilio

Austin, Tex.-based cybersecurity and privacy consulting firm CynergisTek has been acquired by Auxilio, Inc., a provider of document workflow solutions and IT security services based in Mission Viejo, California, in a deal valued at up to $34.3 million.

Healthcare Data Breaches: A Year in Review

The latest year-in-review Breach Barometer report from Protenus paints a stark picture—2016 average at least one health data breach per day, affecting more than 27 million patient records.

Healthcare Industry Could Save $9.4B with Full Adoption of Electronic Transactions

The healthcare industry continues to make modest progress toward full adoption of electronic business transactions, but significant gaps remain, representing an opportunity for $9.4 billion in savings, according to new data from the 2016 CAQH Index.

ONC Announces Phase 2 Winners of Consumer, Provider App Challenges

ONC today announced the Phase 2 winners for the Consumer Health Data Aggregator Challenge and the Provider User Experience Challenge.